Botulism Clinical Trial
Official title:
Pharmacokinetics of Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine) (BAT®) in Pediatric Patients With a Confirmed or Suspected Exposure to Botulinum Neurotoxin
The purpose of this study is to verify the pediatric dosing recommendations for BAT product in pediatric patients that are treated with BAT product due to a confirmed or suspected case of botulism. A minimum of one serum sample should be collected but whenever feasible additional serum samples (up to three per enrolled participant) may be collected from the participant or obtained from surplus standard of care samples, if available, within 32 hours after BAT product administration. Safety of the BAT product will also be evaluated. Emergent will follow-up with the physician by telephone after 30 days post-BAT product administration to collect AEs, SAEs, and unanticipated events.
Primary Objective: To collect blood from pediatric participants to analyze the pharmacokinetics (PK) of BAT product to verify the current US FDA-approved pediatric dosing recommendations for BAT product. Safety Objective: To evaluate the safety of BAT product in pediatric participants. Protocol Design: This is a single arm, multi-site PK study in pediatric patients treated with BAT product. Pharmacokinetic Parameters: The serum concentrations of BAT product obtained will be modeled using a population PK approach based on a previously developed model for BAT serotypes A through G in healthy adult human participants. Safety Endpoints: The incidence of adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESI) that occur within 30 days after BAT product administration. In this study hypersensitivity/allergic reactions including serum sickness, febrile reactions, and hemodynamic instability and bradycardia, as well as reports of an infectious disease transmission will be included as AESI. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03603665 -
A Study to Evaluate the Safety and Pharmacokinetics of NTM-1633 vs Placebo Administered Intravenously in Healthy Adults
|
Phase 1 | |
| Not yet recruiting |
NCT04550793 -
Using Shear Wave Ultrasound Elastography for Follow up After Anti-spastic Intervention Among Stroke Patients
|
||
| Completed |
NCT01441557 -
Pilot Study on the Usefulness of 3,4-diaminopyridine in the Treatment of Botulism
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05769478 -
Effect of Amifampridine on Neuromuscular Transmission in Patients Treated With OnabotulinumtoxinA
|
Phase 1 | |
| Withdrawn |
NCT01940315 -
Phase 3, Randomized, Safety, Lot Consistency and Clinical Benefit Study of Recombinant Botulinum Vaccine A/B
|
Phase 3 | |
| Completed |
NCT02055183 -
BT-010 Registry for the Evaluation of Safety and Clinical Outcomes in Patients Treated With Botulinum Antitoxin
|
||
| Completed |
NCT01357213 -
Phase 1 PK Study of XOMA 3AB
|
Phase 1 | |
| Completed |
NCT03676634 -
Tolerability and Immunogenicity of rBV A/B for the Production of BabyBIG®
|
Phase 2 | |
| Completed |
NCT00314080 -
Treatment of Survivors After Botulism Outbreak
|
N/A | |
| Not yet recruiting |
NCT06112834 -
Tolerability and Immunogenicity of a Single 40-ug Dose of rBV A/B for the Production of BabyBIG®
|
Phase 2 | |
| Completed |
NCT00348426 -
Botulism Outbreak in Thailand (Episode II)
|
Phase 4 | |
| Completed |
NCT00004401 -
Study of Human Botulism Immunoglobulin in Infants With Botulism
|
N/A | |
| Completed |
NCT01701999 -
Safety, Tolerability, and Immunogenicity Study of Investigational Recombinant Botulinum Vaccine A/B (rBV A/B) in Volunteers Previously Immunized With Investigational Pentavalent Botulinum Toxoid
|
Phase 2 | |
| Completed |
NCT02779140 -
Phase I, Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of NTM-1632
|
Phase 1 |